Long-Acting Beta2-Agonist in Addition to Tiotropium Versus Either Tiotropium or Long-Acting Beta2-Agonist Alone for Chronic Obstructive Pulmonary Disease

Prescriber - United Kingdom
doi 10.1002/psb.910
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors

Unknown

Publisher

Wiley

Related search

Long-Acting Beta2-Agonist in Addition to Tiotropium Versus Either Tiotropium or Long-Acting Beta2-Agonist Alone for Chronic Obstructive Pulmonary Disease

Cochrane Database of Systematic Reviews
2015English

Combination Inhaled Steroid and Long-Acting Beta2-Agonist Versus Tiotropium for Chronic Obstructive Pulmonary Disease

2010English

Addition of Long-Acting Beta2-Agonists to Inhaled Corticosteroids Versus Same Dose Inhaled Corticosteroids for Chronic Asthma in Adults and Children

Cochrane Database of Systematic Reviews
2010English

Severe Exacerbation and Pneumonia in COPD Patients Treated With Fixed Combinations of Inhaled Corticosteroid and Long-Acting Beta2 Agonist

International Journal of COPD
EnvironmentalPublic HealthHealth PolicyMedicinePulmonaryRespiratory MedicineOccupational Health
2017English

Combination Long-Acting Β-Agonists and Inhaled Corticosteroids Compared With Long-Acting Β-Agonists Alone in Older Adults With Chronic Obstructive Pulmonary Disease

JAMA - Journal of the American Medical Association
Medicine
2014English

Cost-Effectiveness of Asthma Step-Up Therapy as an Increased Dose of Extrafine-Particle Inhaled Corticosteroid or Add-On Long-Acting Beta2-Agonist

Pulmonary Therapy
2016English

Dual Combination Therapy Versus Long-Acting Bronchodilators Alone for Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Network Meta-Analysis

Cochrane Database of Systematic Reviews
2018English

Tiotropium for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis

Thorax
PulmonaryRespiratory Medicine
2006English

Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease

Drugs - Real World Outcomes
Pharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy